617 related articles for article (PubMed ID: 19220880)
1. Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis.
Sharplin P; Gordon J; Peters JR; Tetlow AP; Longman AJ; McEwan P
Cardiovasc Diabetol; 2009 Feb; 8():9. PubMed ID: 19220880
[TBL] [Abstract][Full Text] [Related]
2. Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study.
Sharplin P; Gordon J; Peters JR; Tetlow AP; Longman AJ; McEwan P
Cardiovasc Diabetol; 2009 Jan; 8():3. PubMed ID: 19152692
[TBL] [Abstract][Full Text] [Related]
3. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
Jacober SJ; Scism-Bacon JL; Zagar AJ
Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
[TBL] [Abstract][Full Text] [Related]
4. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study.
Fritsche A; Larbig M; Owens D; Häring HU;
Diabetes Obes Metab; 2010 Feb; 12(2):115-23. PubMed ID: 20092584
[TBL] [Abstract][Full Text] [Related]
5. Switching from premixed insulin to basal-bolus insulin glargine plus rapid-acting insulin: the ATLANTIC study.
Mathieu C; Storms F; Tits J; Veneman TF; Colin IM
Acta Clin Belg; 2013; 68(1):28-33. PubMed ID: 23627191
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.
Testa MA; Gill J; Su M; Turner RR; Blonde L; Simonson DC
J Clin Endocrinol Metab; 2012 Oct; 97(10):3504-14. PubMed ID: 22851487
[TBL] [Abstract][Full Text] [Related]
7. A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study.
Gordon J; Pockett RD; Tetlow AP; McEwan P; Home PD
Int J Clin Pract; 2010 Nov; 64(12):1609-18. PubMed ID: 20946269
[TBL] [Abstract][Full Text] [Related]
8. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial.
Jia W; Xiao X; Ji Q; Ahn KJ; Chuang LM; Bao Y; Pang C; Chen L; Gao F; Tu Y; Li P; Yang J
Lancet Diabetes Endocrinol; 2015 Apr; 3(4):254-62. PubMed ID: 25754414
[TBL] [Abstract][Full Text] [Related]
9. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
[TBL] [Abstract][Full Text] [Related]
10. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
11. [Post-hoc analyses of type 2 diabetes patients switch from premixed insulin regimen to basal insulin plus oral hypoglycemic agents regimen].
Bu S; Guo XH; Yang WY; Lu GZ; Yang ZJ; Ren TT; Gao Y
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3115-8. PubMed ID: 18269868
[TBL] [Abstract][Full Text] [Related]
12. [Improvement in the glycaemic control of patients after switching from human insulin to insulin glargine-based basal-bolus regimen].
Nagy E; Kovács G
Orv Hetil; 2018 Jul; 159(29):1201-1207. PubMed ID: 30008232
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switch pilot study.
Schiel R; Müller UA
Exp Clin Endocrinol Diabetes; 2007 Nov; 115(10):627-33. PubMed ID: 18058596
[TBL] [Abstract][Full Text] [Related]
14. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy of insulin glargine after switching from NPH insulin as intensive replacement of basal insulin in Japanese diabetes mellitus. Comparison of efficacy between type 1 and type 2 diabetes (JUN-LAN Study 1.2).
Kanazawa Y; Igarashi Y; Komiya K; Sakurai Y; Shimizu T; Fujitani Y; Tanaka Y; Watada H; Kawamori R; Hirose T
Endocr J; 2007 Dec; 54(6):975-83. PubMed ID: 18000343
[TBL] [Abstract][Full Text] [Related]
16. Comparison of insulin glargine versus NPH insulin in people with Type 2 diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin.
Siegmund T; Weber S; Blankenfeld H; Oeffner A; Schumm-Draeger PM
Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):349-53. PubMed ID: 17701878
[TBL] [Abstract][Full Text] [Related]
17. Improved glycaemic control with insulin glargine as part of a basal-bolus regimen in T2DM patients inadequately controlled on premixed therapy.
Buturovic BA; Lekic A; Grulovic N
Med Arch; 2013; 67(5):342-5. PubMed ID: 24601167
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study.
Pfohl M; Siegmund T; Pscherer S; Pegelow K; Seufert J
Vasc Health Risk Manag; 2015; 11():569-78. PubMed ID: 26604774
[TBL] [Abstract][Full Text] [Related]
19. Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus.
Kabadi UM
Clin Drug Investig; 2008; 28(11):697-701. PubMed ID: 18840012
[TBL] [Abstract][Full Text] [Related]
20. Analysis of glycaemic control and weight change in patients initiated with human or analog insulin in an US ambulatory care setting.
McAdam-Marx C; Bouchard J; Aagren M; Nelson R; Brixner D
Diabetes Obes Metab; 2010 Jan; 12(1):54-64. PubMed ID: 19758356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]